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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: Hemophilia involves a lifelong burden from the perspective of the pa-
tient and the entire healthcare system. Advances in genetic testing provide valuable informa-
tion to hemophilia-affected families for family planning. The aim of this study was to analyze
the cost-effectiveness of carrier and prenatal genetic testing in the health-economic frame-
work in Taiwan.
Methods: A questionnaire was developed to assess the attitudes towards genetic testing for
hemophilia. We modeled clinical outcomes of the proposed testing scheme by using the deci-
sion tree method. Incremental cost-effectiveness analysis was conducted, based on data from
the National Health Insurance (NHI) database and a questionnaire survey.
Results: From the NHI database, 1111 hemophilic patients were identified and required an
average medical expenditure of approximately New Taiwan (NT) $2.1 million per patient-
year in 2009. By using the decision tree model, we estimated that 26 potential carriers need
to be tested to prevent one case of hemophilia. At a screening rate of 79%, carrier and prenatal
genetic testing would cost NT $85.9 million, which would be offset by an incremental saving of
NT $203 million per year by preventing 96 cases of hemophilia. Assuming that the life expec-
tancy for hemophilic patients is 70 years, genetic testing could further save NT $14.2 billion.
Higher screening rates would increase the savings for healthcare resources.
Conclusion: Carrier and prenatal genetic testing for hemophilia is a cost-effective investment
in healthcare allocation. A case management system should be integrated in the currenthave no conflicts of interest relevant to this article.
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Cost-effectiveness of genetic tests for hemophilia 723practice to facilitate patient care (e.g., collecting family pedigrees and providing genetic
counseling).
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Hemophilia A and hemophilia B are X-linked recessive
bleeding disorders caused by a deficiency of factor VIII and
factor IX, respectively. Males with defective genes are
symptomatic with diverse clinical severity, whereas
females are usually asymptomatic carriers of the genes.
The worldwide occurrence is estimated to affect 1 per 5000
newborn males for hemophilia A and 1 per 30,000 newborn
males for hemophilia B.1 Patients and their families may
bear a heavy disease burden associated with uncertain
and excessive bleeding, risks of transfusion-related infec-
tion, frequent outpatient and inpatient visits, loss of life
quality, and care-related emotional distress.2e5 Because
the development of recombinant clotting factors has
greatly improved the healthcare and health status of he-
mophilic patients, financial expenditures on hemophilia-
related treatments are expanding, largely because of the
growing costs of these novel pharmacological therapies.6,7
To effectively reduce the recurrence of this disease, it is
important to provide as much medical information as
possible for the decision-making of families at risk for
hemophilia.8
Attitudes towards genetic testing in the hemophilia
community also need to be considered. Many individual and
socioenvironmental factors may influence the option of
predictive and carrier testing for inherited diseases.9 Dis-
cussions usually involve who can give consent and when to
perform the test.10e12 The main concerns include disclosure
of genetic confidentiality, psychosocial stigmatization,
emotional distress of future disabilities, and prenatal
violation of the right to life if artificial abortion is
adopted.13e15 However, both healthcare providers and the
hemophilia community also argue the potential advantages
of genetic testing in that it may provide anticipatory
guidance in healthcare for affected patients and fetuses at
risk of hemophilia, and it may provide reproductive options
for female carriers.12,16 Therefore, thorough psychosocial
evaluation and family counseling may be needed before the
implementation of genetic testing in clinical practice.
Screening for hemophilia could previously be performed
by testing the level of factor VIII or factor IX coagulation
activity in blood.17,18 Measurement of coagulation activity
is correlated with clinical severity; however, this technique
is unable to provide genetic information in prenatal diag-
nosis. Recent advancements in molecular technology have
introduced several rapid and sensitive mutational analyses
of defective genes.18e21 Genetic testing of the factor VIII
(F8) gene and the factor XI (F9) gene in carrier screening
and prenatal diagnosis for hemophilia is possible and reli-
able. Costs for this technique are also steadily declining
because of technical improvements and massive applica-
tion. However, overuse of unnecessary genetic testing that
is mismatched to health needs may lead to accruement of
medical expenditures that exceed the potential savingsfrom disease prevention.13,22 In a resource-limited setting,
a key criterion for funding decisions relies on a certain
balance between the economic costs and health benefits.
Invasive prenatal sampling of fetal cells incurs a certain risk
of miscarriage. Before health authorities provide medical
allowances for genetic testing, an economic analysis
framework in the context of ethical, social, and legal as-
pects must be applied.23 The aim of this study was to
investigate the cost-effectiveness of carrier detection and
prenatal diagnosis for hemophilia. Results of the economic
evaluations are expected to provide insight into the
improvement of healthcare for hemophilic patients and
their relatives.Methods
Decision analysis
A decision tree model was applied to evaluate the cost-
effectiveness of hemophilia carrier detection and prenatal
diagnosis by using the TreeAge Pro decision analysis soft-
ware (TreeAge Pro 2012; TreeAge Software Inc., One Bank
Street Williamstown, MA 01267, USA). We performed eco-
nomic and clinical comparisons between two hypothesized
scenariosdnamely, with genetic testing and without ge-
netic testing.
Study participants
To obtain opinions and construct the questionnaire, we
performed in-depth interviews with focus groups. Focus
group members consisted of hematologists, genetic coun-
selors, sociologists, legal scholars, and hemophilic patients
and their family members. For the survey of public opinions
regarding genetic testing for hemophilia, healthy females
of childbearing age were recruited from multiple sources.
Hemophilic patients and their family members were
recruited from a convenient sample in two medical centers.
All interviews and questionnaire surveys were approved
by the Institutional Review Board of the participating
hospitals.
Estimates of attitudes toward prenatal screening
A questionnaire was specifically designed to explore atti-
tudes toward prenatal genetic testing. We asked re-
spondents concerning their willingness to receive a carrier
and prenatal genetic test for hemophilia, willingness to
conceive a baby, and willingness to continue a pregnancy if
the prenatal genetic test was positive for hemophilia. To
encompass the minimum and maximum prevention effects
of the genetic test, we modeled high and low screening
rates in our analysis.
724 M.-C. Tsai et al.Estimates of healthcare costs for hemophilic
patients
Economic evaluations of the cost-effectiveness analysis
involved medical and nonmedical perspectives. Medical
costs included direct expenditures of outpatient and inpa-
tient service use and out-of-pocket healthcare-related ex-
penses (e.g., alcohol swabs and cotton wools), whereas
nonmedical costs included loss of work productivity and
travel expenses to medical facilities. With regard to
comprehensive coverage, direct medical expenditure and
the present number of hemophilic patients were retrieved
from the database of the National Health Insurance (NHI)
program in Taiwan.24 Annual medical expenditure per per-
son was hence estimated by the annual total medical
expenditure divided by the maximum number of hemophilic
patients in a single year. We also used the claims data for
hemophilia-related healthcare use from the NHI database
to obtain an annual estimate of clinical visits per person.
Estimation of out-of-pocket healthcare-related expenses
and nonmedical costs were based on the results of the
aforementioned purposive questionnaire survey conducted
on hemophilic patients.
Estimates of costs and accuracy of genetic testing
Methodological differences may affect the accuracy and
cost of genetic tests for hemophilia. The combined use of
direct sequencing and denaturing high-performance liquid
chromatography (DHPLC) could elevate the accuracy rate
to 96% and was therefore implemented in our model for
analysis.19,25,26 In current practice, the cost of genetic
testing for hemophilia ranges from New Taiwan (NT) $4500
to NT $25,000, depending on the complexity of responsible
genes and technical requirements for the analysis of rare or
hot mutational spots. Hence, we assumed the highest
possible cost of genetic testing in our scenario. The
procedure-related cost (e.g., service fees, device ex-
penses, and costs for prenatal amniocentesis and kar-
yotyping) was moreover added into the total cost of the
genetic test. We modeled a genetic test costing NT $25,510
and a prenatal chromosome study with amniocentesis
costing NT$ 34,000.
Estimates of target population for genetic tests
Because there is no available data regarding the exact
number of hemophilic carriers in Taiwan, we assumed 277
potential carrier women for every 100 affected men and
that one-half of these potential carriers would be true
carriers, based on published literature.27 We modeled a
target population based on the estimated number of pre-
sent hemophilic patients multiplied by the ratio of poten-
tial carrier females to affected males.
Incremental cost-effectiveness analysis
Our prediction model required a number of assumptions.
First, we estimated that the life expectancy for hemophilic
patients is 70 years. This assumption was based on previous
studies showing that hemophilic patients had a shorter lifeexpectancy than the general population by 5e15 years on
average.28,29 Second, we assumed that opportunities for
healthcare utilization would be equal throughout the entire
lifetime. Third, we assumed that costs and health outcomes
in future years would not be discounted or inflated. The
incremental costs and savings per hemophilia case that
were prevented were calculated by comparing the costs
and effects in the hypothesized scenarios with and without
genetic tests for hemophilia.
Results
Attitudes toward prenatal screening
Convenience sampling was employed and consisted of 30
hemophilic patients and 41 female relatives of these pa-
tients. For their counterparts, 788 healthy females of
childbearing age were recruited. Among the female rela-
tives of the hemophilic patients, 79% of the women were
willing to receive a genetic test for hemophilia; 71% of the
women were willing to have a child if they tested positive
as a hemophilia carrier; 85% of the women were willing to
have a prenatal screening test if they were pregnant; and
28% of the women with a positive prenatal test for hemo-
philia were willing to give birth to an affected boy. By
contrast, 97% of the healthy females were willing to receive
a genetic test for hemophilia if they had hemophilic rela-
tives; 51% of healthy females were willing to have a child if
they tested positive as a hemophilia carrier; 98% of healthy
females were willing to have a prenatal screening test for
hemophilia if they were pregnant; and 33% of healthy fe-
males with a positive prenatal test for hemophilia were
willing to give birth to an affected boy. Based on the
aforementioned results, we modeled high (97%) and low
(79%) screening rates in the subsequent cost-effectiveness
analysis.
Healthcare costs for hemophilic patients
We employed the claims data for hemophilia-related
healthcare from the NHI database. The mean clinical visit
value was approximately 25 times for one patient per year.
On average, they spent 4 hours (travel time included) for
each clinical visit. The minimum wage of NT $98/hour in
2011 was used to calculate the preceding earnings because
of clinical visits,30 and an average amount of NT $220 for
travel to and from the medical service was reported by the
surveyed patients.
Effects of carrier prenatal genetic tests
From the NHI database, we identified 1111 hemophilic pa-
tients in 2009. By multiplying by the ratio of female carriers
to male patients, we estimated there were 3078 potential
hemophilia carriers in Taiwan. Without any intervention,
196 newborn males are assumed to be affected with he-
mophilia. According to our scheme for carrier prenatal
screening, there would be 2432 potential carriers tested
and the prevented births of 96 hemophilic newborns, based
on a screening rate of 79%; 554 more carriers would be
Figure 1 The decision tree model for carrier and prenatal genetic testing for hemophilia at the screening rate of (A) 79% and (B)
97%.
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Table 1 Expenditures of medical care for hemophilic patients [in New Taiwan (NT) dollars].
Year No. of
patients
Outpatient
costs
Inpatient
costs
Total costs Costs per
patient-year
Medication
costs
Medication
costs (%)
2002 881 784,471,365 73,761,813 858,233,178 974,158 837,517,191 97.59
2003 907 925,273,485 87,742,743 1,013,016,228 1,116,887 994,358,679 98.16
2004 946 1,044,484,666 97,517,372 1,142,002,038 1,207,190 1,119,411,753 98.02
2005 931 1,288,663,531 156,216,322 1,444,879,853 1,551,965 1,420,505,522 98.31
2006 979 1,512,737,373 148,924,092 1,661,661,465 1,697,305 1,635,971,217 98.45
2007 1024 1,770,764,448 175,864,512 1,946,628,960 1,901,005 1,918,712,788 98.57
2008 1068 2,042,505,236 213,003,569 2,255,508,805 2,111,900 2,227,555,725 98.76
2009 1111 2,132,631,605 193,316,456 2,325,948,061 2,093,563 2,296,683,277 98.74
726 M.-C. Tsai et al.tested and the births of 21 more hemophilic patients would
be prevented if the screening rate were augmented to 97%
(Fig. 1). The testing of 26 carriers on average is needed to
prevent the birth of one hemophilic male newborn.
Healthcare expenditures for hemophilic patients
According to the NHI research database, the registered
number of hemophilic patients increased from 881 patients
in 2002 to 1111 patients in 2009 (Table 1). The mean
number of newly diagnosed patients was 33 patients per
year. The direct medical cost for hemophilic patients
peaked in 2009 with a total amount of approximately NT
$2.1 million per person, but most (98%) of this cost was
attributed to pharmacological products. From the patient’s
perspective, out-of-pocket healthcare-related expendi-
tures cost NT $466 per month, whereas an absence from
work costs NT $392 per clinical visit. In total, the health-
care expenditure for hemophilic patients was estimated as
NT $2,114,455 per patient-year.
Incremental cost-effectiveness ratio
Table 2 shows the incremental cost-effective ratio of the
proposed scheme of carrier and prenatal genetic testing in
comparison to the current practice. In the analysis, the
total amount of NT $1,219,473 at the screening rate of 79%Table 2 Estimates of health outcomes with and without geneti
Events, n No genet
Hemophilic patients
Terminated hemophilic fetuses
Costs for hemophilia care, NT $
Direct medical costs 410,338,
Healthcare-related costs 1,096,
Non-medical costs 2,998,
Total costs 414,433,
Costs for genetic testing, NT $
Costs for carrier genetic testing
Costs for amniocentesis and chromosome study
Costs for fetal genetic testing
Total costs
Incremental cost-effectiveness ratio
NT $ Z New Taiwan dollars.and NT $1,212,822 at the screening rate of 97% would be
saved per life year prevented. Given an average life ex-
pectancy of 70 years for hemophilic patients, the sum of
savings was estimated to reach NT $8.2 billion at the
screening rate of 79% and NT $9.9 billion at the screening
rate of 97%.
Discussion
According to the NHI research database, the medical
expenditure for hemophilic patients per year has tripled
and the medical expenditure per patient-year doubled from
the years of 2002 to 2009. The causes of the incremental
costs could largely be attributed to growing acquisition
prices of novel pharmacological products, evolutional con-
cepts in prophylaxis treatment, advancements in health-
care that result in a longer life expectancy, and increased
surgical needs such as arthroplasty.7,23,31 Many previous
studies comparing the cost-effectiveness between prophy-
lactic use and on-demand use of coagulation factors have
been in favor of adding the costs of prophylaxis treatment
that prevent bleeding episodes.28,32 The demand for ther-
apeutic treatment nevertheless remains an expanding
burden on healthcare resources.33,34 The number of newly
diagnosed patients therefore has not reduced. We observed
that recurrent hemophilic patients from the same carrier
mother were rare, but prenatal screening was not prevalentc testing.
ic testing 79% Screening rate 97% Screening rate
196 100 79
0 96 117
348 209,356,300 165,391,477
032 559,200 441,768
800 1,530,000 1,208,700
180 211,445,500 167,041,945
0 62,040,320 76,172,860
0 20,230,000 24,854,000
0 3,647,930 4,464,250
0 85,918,250 105,491,110
1,219,473 1,212,822
Cost-effectiveness of genetic tests for hemophilia 727among female relatives of affected males. There were also
sporadic cases, comprising 30% of the hemophilia commu-
nity, that are unpreventable by carrier testing.1,31 With the
advancement of molecular technology, accurate prenatal
diagnosis has been proven to be achievable and effective in
preventing the birth of children with hemophilia.35
Based on the decision tree method, our analysis suggests
that investment in genetic testing for potential carriers in
hemophilic families will yield cost savings in healthcare
expenditures related to this disease. Having 26 potential
pregnant carriers receive prenatal screening would add an
approximate incremental cost of NT $1.6 million, but pre-
vent the birth of a newborn with hemophilia, which is a
saving of NT $2.1 million per life year and will avert a total
of 70 life years per patient. To maximize the effect size of
our proposed diagnostic scheme, the screening rate is an
important determinant of its success. At an additional cost
of NT $19.6 million to increase the screening rate from 79%
to 97%, we expect to prevent 21 more cases of hemophilia,
and consequently further save 1470 life years and NT $3
billion in future costs. A case management system has been
introduced as a practical and integrative tool in the field of
healthcare for hemophilic patients. Such a healthcare sys-
tem may facilitate collecting family pedigrees, identifying
potential female carriers, coordinating health professionals
in providing health services, counseling patients and fam-
ilies about diseases, and hence may increase the likelihood
of accepting genetic testing.34,36
Another factor that warrants attention is the ethical
issues raised in the discussion of providing genetic testing
to the hemophilia community. Universal screening may
violate personal genetic privacy and deprive patients of the
right to consent in medical care.12,13,15,22 Decisions
regarding receiving prenatal diagnosis and termination of
affected pregnancies are complex and determined by per-
sonal, cultural, and ethical factors.9,11,37 Prenatal diagnosis
should not simply be used as a justification for reproductive
termination. In our survey, a lower percentage of hemo-
philic families opted for genetic testing compared to their
healthy counterparts. Possible reasons hemophilic families
less frequently opt for genetic testing include the fear of
conceiving an affected baby, guilty feelings and/or denial
of being the carrier of the causative genes, and abstention
from reproduction. Some people were also concerned
about revealing the genetic results to their partner because
this would cause pressure on the carriers because of the
stigmatization of this disease. By contrast, options for ge-
netic testing were primarily for the sake of medical care
and lifestyle. For example, if a female relative of a he-
mophiliac knows she is a carrier, she may wish to know how
to prevent the occurrence in future pregnancies or prepare
for specific obstetrical precautions. Because of this, ge-
netic counseling is vital before and after diagnostic testing
for hemophilia. Female relatives at risk of having a carrier
status should be advised of the possible psychological
impacts resulting from the outcome of predictive testing.
The decision of to whom to disclose the hereditary infor-
mation also needs to be individualized in the counseling
discussion.
There are some limitations in the present study in
interpreting the results. First, our estimation was primarily
based on the NHI database. We were unable to accessindividual insurance claims and therefore assumed that
medical expenditure was equal across all ages. However,
demands for hemostatic therapy are mostly dependent on
the level of physical activity and risk of trauma, which peak
in young adulthood.28 Costs for hemophilia treatment per
life year may be overestimated in the first several years of
childhood. In actuality, children with hemophilia require
lifelong therapy that eventually equals the costs of prena-
tal testing. Second, the diagnostic process is modified for
simplicity in our scenario-based analysis. The index case
may need genotyping in the very beginning before the fe-
male relatives receive carrier testing. A sequential geno-
typing strategy is required for detecting a vast variety of
genetic defects such as inversion, insertions or deletions,
and point mutations. These techniques may include poly-
merase chain reaction for detecting intron inversions,
DHPLC, or newer techniques such as high-resolution
melting analysis (for detecting small insertions and
deletions) and direct sequencing (for detecting point mu-
tations).19,26,38 Despite the evolution of molecular tech-
niques, the feasibility of genetic testing in hemophilia A
and hemophilia B should warrant cautious attention that
mutant alleles may exist beyond the scope of our current
examination. The cost-effectiveness of our proposed
scheme can be influenced by the proportion of pregnancies
in which the women opt for termination. Reproductive
opinions expressed by the limited number of hemophilic
families in this study may not be generalized to the whole
community. Further research on the attitudes toward and
beliefs about genetic testing among Taiwanese patients and
their families is needed to tailor the policy so that it is more
applicable to local situations.
In conclusion, carrier and prenatal genetic testing for
hemophilia is a cost-effective investment in saving future
healthcare expenditures of this disease. We recommend
that prenatal genetic diagnosis should be promoted under
ethical, social, and legal aspects. In current practice, a
case management system should meanwhile be integrated
for its benefits in improving the efficiency of healthcare
provided to patients and families.Acknowledgments
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